Sign in
TerminatedNo phase

Predicting Cognitive Decline From Androgen Deprivation Therapy

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Status
Terminated
People taking part
32 people enrolled
Started
22 May 2023
Ended
30 Apr 2026
Type of study
Observational, 3 groups
Treatments tested
  • Blood-based assay
  • Cognitive assessments
  • Quality of Life Surveys
Record updated
7 May 2026
Why it stopped
Slow Accrual

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Patient Participants-
  • Age 18 years or greater
  • Fluent in reading, listening to, and writing English
  • Current or prior diagnosis of prostate adenocarcinoma based on a pathology report or as documented in a medical oncology, urology, or radiation oncology note
  • Access and ability to use a computer or mobile device with Internet connectivity to complete study procedures
  • Telephone Montreal Cognitive Assessment (T-MoCA) of 16 or greater
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (documented within past 3 months, otherwise patient-reported); Study partner participants-
  • Age 18 years or greater
  • Fluent in reading, listening to, and writing English
  • Identified by patient participant as a person who knows patient participant well, like a friend, family member or spouse
  • Access and ability to use a computer or mobile device with internet connectivity to complete study procedures; Only the ADT cohort-
  • Anticipated to start ADT, which includes one of the following two treatments; Gonadotropin-releasing hormone (GnRH) agonist (e.g., leuprolide, goserelin, and others); GnRH antagonist (i.e., degarelix or relugolix)
  • Anticipated to remain on ADT for at least 12 months
  • Concurrent first-generation anti-androgens (e.g., bicalutamide, flutamide, nilutamide) and novel androgen-signaling inhibitors (e.g., abiraterone, enzalutamide, and apalutamide) are allowed
  • Concurrent radiation is allowed; Only the PC cohort-
  • Has completed definitive local therapy (radical prostatectomy or radiation therapy) for localized prostate cancer at least 6 months prior to screening
  • For radical prostatectomy: undetectable prostate-specific antigen (PSA) within 12 months of screening
  • For radiation therapy: last PSA of < 2.0 within 12 months of screening

Who cannot take part

  • Receipt of ADT (GnRH agonist, GnRH antagonist, 1st-generation anti-androgen, or novel androgen signaling inhibitor) within 6 months before screening. ADT >6 months prior to screening is allowed provided testosterone has recovered to 100 ng/ml or greater
  • Concurrent or anticipated (at any point during first 12 months of ADT) non-hormonal, antineoplastic systemic therapy, such as chemotherapy
  • Prior or concurrent brain metastases (no prior or screening imaging is required)
  • Prior or concurrent malignancy other than prostate cancer whose natural history or treatment has the potential to interfere with study assessments; Study partner participants-
  • Any prior, concurrent, or anticipated use of any hormonal systemic therapy, including GnRH agonist, GnRH antagonist, 1st-generation anti-androgen, or novel androgen signaling inhibitor
  • Any known or prior history of M1 prostate cancer (no screening imaging required)
  • Current or prior biochemical recurrence following American Urological Association guidelines for radical prostatectomy or American Society for Therapeutic Radiology and Oncology (ASTRO) guidelines for radiation therapy
  • Major neurocognitive or psychiatric disorders, such as dementia or schizophrenia
  • Patient Participants-
  • Small cell prostate carcinoma (pure or mixed)
  • Testosterone <100 ng/ml
  • None; Only the ADT cohort-
  • None; Only the PC cohort-

Where in United States

  • University of California San FranciscoSan Francisco, United States

About the trial

What the trial wants to find out

Androgen Deprivation Therapy (ADT) is associated with cognitive impairment and dementia in men with prostate cancer. Pre-clinical data suggest that ADT-induced hypogonadism leads to accumulation of beta-amyloid plaques in the hippocampus, a pathological hallmark of Alzheimer's Disease (AD). Neuroimaging Functional magnetic resonance imaging (fMRI) studies also demonstrate that ADT decreases metabolic activity in the parietal, occipital, and prefrontal cortices. Multiple prospective cohort and population-based clinical studies have been conducted to test the association between ADT and cognitive impairment and/or dementia.

Read full original descriptionShow less

Plasma biomarkers have been developed to predict brain amyloidosis, a key pathological feature of AD and a risk factor for developing dementia due to AD. The advantage of a blood-based assay is the lower cost, invasiveness, and time compared to cerebrospinal fluid (CSF) and Positron Emission Tomography (PET)-based biomarkers.

The 3 groups in the trial

  • Participants with prostate cancer, ADT (ADT Cohort)

    This group is comprised of adult men with hormone-sensitive prostate cancer who are starting androgen deprivation therapy as part of standard of care prostate cancer (not as part of this protocol).

    Treatment: Blood-based assay, Cognitive assessments, and Quality of Life Surveys

  • Participants in remission, No ADT (Prostate cancer Control (PC) Cohort))

    This group is comprised of adult men who are in remission from prostate cancer who have never received ADT.

    Treatment: Blood-based assay, Cognitive assessments, and Quality of Life Surveys

  • Partners of Participants

    Study partner participants will also be recruited

    Treatment: Quality of Life Surveys

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Plasma Amyloid-beta 42/40 to Predict Cognitive Decline From Androgen Deprivation Therapy in Prostate Cancer: a Prospective Observational Study
Record updated
7 May 2026